Kinarus Revenue and Competitors

Basel,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Kinarus's estimated annual revenue is currently $1.2M per year.(i)
  • Kinarus's estimated revenue per employee is $201,000

Employee Data

  • Kinarus has 6 Employees.(i)
  • Kinarus grew their employee count by -50% last year.

Kinarus's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Kinarus?

Kinarus AG is a clinical-stage pharmaceutical company focused on bringing novel, patient-focused treatments, for viral, respiratory, and ophthalmic diseases. Kinarus was incorporated in Basel, Switzerland in 2017. Our lead drug candidate is an oral combination of a clinical-stage P38 mitogen activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, and a second drug, together enabling an oral, long-term effective treatment. Kinarus is preparing for a rapid launch of a Phase 2 clinical trial in hospitalized Covid-19 patients with the aim to reduce mortality and duration of hospital stay. The mechanism of action of our candidate is three-fold; reducing viral replication, inflammation, and organ damage. Kinarus has also obtained regulatory approval for a one-year Phase 2 clinical trial in patients diagnosed with wet Age-Related Macular Degeneration. Injectable agents targeting vascular endothelial growth factor are the only approved therapies. Despite the availability of these drugs, real-world data shows significant under-treatment leading to progressive loss of vision and blindness. Kinarus's drug candidate, administered on top of anti-VEGF agents, has the potential to reduce injection frequency, providing additional therapeutic benefit and relieving the high burden to patients and their caregivers.

keywords:N/A

N/A

Total Funding

6

Number of Employees

$1.2M

Revenue (est)

-50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kinarus News

2022-04-17 - Kinarus-Aktionäre stimmen Reverse Takeover durch Perfect Holding zu | Finanz und Wirtschaft

Die Verschmelzung von Perfect Holding mit Kinarus kommt voran. Deren Aktionäre haben der Transaktion zugestimmt. Drucken.

2022-04-17 - Les actionnaires de Kinarus acceptent la fusion inversée avec Perfect Holding

Zurich (awp) - Les actionnaires de la société biopharmaceutique bâloise Kinarus ont donné leur accord en vue de son acquisition prévue par...

2022-04-06 - Kinarus darf Coronastudie fortsetzen | Unternehmen Gesundheit | Finanz und Wirtschaft

Kinarus kann ihre Phase-II-Studie an hospitalisierten Coronapatienten weiterführen. Das Gremium, das die Studie überwacht,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M7-12%N/A
#2
$0.6M814%N/A
#3
$0.6M8N/AN/A
#4
$0.4M8-11%N/A
#5
$2.3M9-50%N/A